Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection
is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess formation. The rising incidence of multidrug resistance among isolates has increased both the economic burden and the morbidity and mortality asso...
Saved in:
| Published in | Antimicrobial agents and chemotherapy Vol. 61; no. 11 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
01.11.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess formation. The rising incidence of multidrug resistance among
isolates has increased both the economic burden and the morbidity and mortality associated with
disease and necessitates a search for novel therapeutics. Previous work from our group detailed novel phenoxyacetamide inhibitors that block type III secretion and injection into host cells
In this study, we used a mouse model of
abscess formation to test the
efficacy of these compounds against the
type III secretion system (T3SS). Bacteria used the T3SS to intoxicate infiltrating neutrophils to establish abscesses. Despite this antagonism, sufficient numbers of functioning neutrophils remained for proper containment of the abscesses, as neutrophil depletion resulted in an increased abscess size, the formation of dermonecrotic lesions on the skin, and the dissemination of
to internal organs. Consistent with the specificity of the T3SS-neutrophil interaction,
bacteria lacking a functional T3SS were fully capable of causing abscesses in a neutropenic host. Phenoxyacetamide inhibitors attenuated abscess formation and aided in the immune clearance of the bacteria. Finally, a
strain resistant to the phenoxyacetamide compound was fully capable of causing abscess formation even in the presence of the T3SS inhibitors. Together, our results further define the role of type III secretion in murine abscess formation and demonstrate the
efficacy of phenoxyacetamide inhibitors in
infection. |
|---|---|
| AbstractList | Pseudomonas aeruginosa
is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess formation. The rising incidence of multidrug resistance among
P. aeruginosa
isolates has increased both the economic burden and the morbidity and mortality associated with
P. aeruginosa
disease and necessitates a search for novel therapeutics. Previous work from our group detailed novel phenoxyacetamide inhibitors that block type III secretion and injection into host cells
in vitro
. In this study, we used a mouse model of
P. aeruginosa
abscess formation to test the
in vivo
efficacy of these compounds against the
P. aeruginosa
type III secretion system (T3SS). Bacteria used the T3SS to intoxicate infiltrating neutrophils to establish abscesses. Despite this antagonism, sufficient numbers of functioning neutrophils remained for proper containment of the abscesses, as neutrophil depletion resulted in an increased abscess size, the formation of dermonecrotic lesions on the skin, and the dissemination of
P. aeruginosa
to internal organs. Consistent with the specificity of the T3SS-neutrophil interaction,
P. aeruginosa
bacteria lacking a functional T3SS were fully capable of causing abscesses in a neutropenic host. Phenoxyacetamide inhibitors attenuated abscess formation and aided in the immune clearance of the bacteria. Finally, a
P. aeruginosa
strain resistant to the phenoxyacetamide compound was fully capable of causing abscess formation even in the presence of the T3SS inhibitors. Together, our results further define the role of type III secretion in murine abscess formation and demonstrate the
in vivo
efficacy of phenoxyacetamide inhibitors in
P. aeruginosa
infection. ABSTRACT Pseudomonas aeruginosa is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess formation. The rising incidence of multidrug resistance among P. aeruginosa isolates has increased both the economic burden and the morbidity and mortality associated with P. aeruginosa disease and necessitates a search for novel therapeutics. Previous work from our group detailed novel phenoxyacetamide inhibitors that block type III secretion and injection into host cells in vitro . In this study, we used a mouse model of P. aeruginosa abscess formation to test the in vivo efficacy of these compounds against the P. aeruginosa type III secretion system (T3SS). Bacteria used the T3SS to intoxicate infiltrating neutrophils to establish abscesses. Despite this antagonism, sufficient numbers of functioning neutrophils remained for proper containment of the abscesses, as neutrophil depletion resulted in an increased abscess size, the formation of dermonecrotic lesions on the skin, and the dissemination of P. aeruginosa to internal organs. Consistent with the specificity of the T3SS-neutrophil interaction, P. aeruginosa bacteria lacking a functional T3SS were fully capable of causing abscesses in a neutropenic host. Phenoxyacetamide inhibitors attenuated abscess formation and aided in the immune clearance of the bacteria. Finally, a P. aeruginosa strain resistant to the phenoxyacetamide compound was fully capable of causing abscess formation even in the presence of the T3SS inhibitors. Together, our results further define the role of type III secretion in murine abscess formation and demonstrate the in vivo efficacy of phenoxyacetamide inhibitors in P. aeruginosa infection. Pseudomonas aeruginosa is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess formation. The rising incidence of multidrug resistance among P. aeruginosa isolates has increased both the economic burden and the morbidity and mortality associated with P. aeruginosa disease and necessitates a search for novel therapeutics. Previous work from our group detailed novel phenoxyacetamide inhibitors that block type III secretion and injection into host cells in vitro In this study, we used a mouse model of P. aeruginosa abscess formation to test the in vivo efficacy of these compounds against the P. aeruginosa type III secretion system (T3SS). Bacteria used the T3SS to intoxicate infiltrating neutrophils to establish abscesses. Despite this antagonism, sufficient numbers of functioning neutrophils remained for proper containment of the abscesses, as neutrophil depletion resulted in an increased abscess size, the formation of dermonecrotic lesions on the skin, and the dissemination of P. aeruginosa to internal organs. Consistent with the specificity of the T3SS-neutrophil interaction, P. aeruginosa bacteria lacking a functional T3SS were fully capable of causing abscesses in a neutropenic host. Phenoxyacetamide inhibitors attenuated abscess formation and aided in the immune clearance of the bacteria. Finally, a P. aeruginosa strain resistant to the phenoxyacetamide compound was fully capable of causing abscess formation even in the presence of the T3SS inhibitors. Together, our results further define the role of type III secretion in murine abscess formation and demonstrate the in vivo efficacy of phenoxyacetamide inhibitors in P. aeruginosa infection. is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess formation. The rising incidence of multidrug resistance among isolates has increased both the economic burden and the morbidity and mortality associated with disease and necessitates a search for novel therapeutics. Previous work from our group detailed novel phenoxyacetamide inhibitors that block type III secretion and injection into host cells In this study, we used a mouse model of abscess formation to test the efficacy of these compounds against the type III secretion system (T3SS). Bacteria used the T3SS to intoxicate infiltrating neutrophils to establish abscesses. Despite this antagonism, sufficient numbers of functioning neutrophils remained for proper containment of the abscesses, as neutrophil depletion resulted in an increased abscess size, the formation of dermonecrotic lesions on the skin, and the dissemination of to internal organs. Consistent with the specificity of the T3SS-neutrophil interaction, bacteria lacking a functional T3SS were fully capable of causing abscesses in a neutropenic host. Phenoxyacetamide inhibitors attenuated abscess formation and aided in the immune clearance of the bacteria. Finally, a strain resistant to the phenoxyacetamide compound was fully capable of causing abscess formation even in the presence of the T3SS inhibitors. Together, our results further define the role of type III secretion in murine abscess formation and demonstrate the efficacy of phenoxyacetamide inhibitors in infection. |
| Author | Moir, Donald T Bowlin, Terry L Bowlin, Nicholas O Berube, Bryan J Hauser, Alan R Murphy, Katherine R Williams, John D Torhan, Matthew C |
| Author_xml | – sequence: 1 givenname: Bryan J surname: Berube fullname: Berube, Bryan J organization: Department of Microbiology/Immunology, Northwestern University, Chicago, Illinois, USA – sequence: 2 givenname: Katherine R surname: Murphy fullname: Murphy, Katherine R organization: Department of Microbiology/Immunology, Northwestern University, Chicago, Illinois, USA – sequence: 3 givenname: Matthew C surname: Torhan fullname: Torhan, Matthew C organization: Microbiotix, Inc., Worcester, Massachusetts, USA – sequence: 4 givenname: Nicholas O surname: Bowlin fullname: Bowlin, Nicholas O organization: Microbiotix, Inc., Worcester, Massachusetts, USA – sequence: 5 givenname: John D surname: Williams fullname: Williams, John D organization: Microbiotix, Inc., Worcester, Massachusetts, USA – sequence: 6 givenname: Terry L surname: Bowlin fullname: Bowlin, Terry L organization: Microbiotix, Inc., Worcester, Massachusetts, USA – sequence: 7 givenname: Donald T surname: Moir fullname: Moir, Donald T organization: Microbiotix, Inc., Worcester, Massachusetts, USA – sequence: 8 givenname: Alan R surname: Hauser fullname: Hauser, Alan R email: ahauser@northwestern.edu organization: Department of Medicine, Northwestern University, Chicago, Illinois, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28807906$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kVFrFDEUhYNU7Lb65rPMo4JTb2YmmcmLsCytDlQUrM_hzuRON2UnWZOZ4v4k_6XZ3VoUFEJCki_n5p5zxk6cd8TYSw4XnBfNu-VydQG8gCLn9RO24KCaXAolT9gCQMq8aqA6ZWcx3kHaCwXP2GnRNFArkAv2sx232E-ZH7Kb3Zaytm2zr9QHmqx32eUwUD_5EDN0Zs98WZPzP3bY04SjNYl3a9vZA_JviTSWXewpxuzKhxEPh9ZlmH3yc6Q0G9ocpCPNxo_eYapGYb61zkdMBfZfSI-es6cDbiK9eFjP2bery5vVx_z684d2tbzOseLNlKtOcFWqASuDSCA6UypoqBIABUoyVFV9LaAqa-D9QEXXN43oZC07QCOMKc_Z-6Pudu5GMj25KeBGb4MdMey0R6v_vnF2rW_9vRZSiOR-Enj9IBD895nipEebDNhs0FFqWXNVKA5Cgkzo2yPaBx9joOGxDAe9T1endPUhXc3rhL854hjHQt_5ObjkxP_YV3-28Sj8O_ryFxA5sV4 |
| CitedBy_id | crossref_primary_10_1080_21505594_2020_1776979 crossref_primary_10_1099_mic_0_001401 crossref_primary_10_3389_fcimb_2020_597517 crossref_primary_10_3389_fmicb_2022_831037 crossref_primary_10_3390_d14050345 crossref_primary_10_17116_molgen2020380113 crossref_primary_10_1021_acscentsci_9b00452 crossref_primary_10_3390_biom11060892 crossref_primary_10_1099_mic_0_000778 crossref_primary_10_1128_ecosalplus_esp_0032_2018 crossref_primary_10_1016_j_micpath_2021_104907 crossref_primary_10_1007_s00253_019_10290_7 crossref_primary_10_1080_21505594_2021_1926408 crossref_primary_10_1128_JB_00055_20 crossref_primary_10_3389_fmicb_2019_00573 crossref_primary_10_3390_antib9030035 crossref_primary_10_1016_j_toxicon_2022_09_004 crossref_primary_10_3390_molecules26247635 crossref_primary_10_1074_jbc_RA119_012102 crossref_primary_10_1002_ange_201804971 crossref_primary_10_3390_microorganisms9122424 crossref_primary_10_1111_apm_13119 crossref_primary_10_1039_C9MD00146H crossref_primary_10_1021_acsinfecdis_8b00112 crossref_primary_10_1111_1462_2920_14692 crossref_primary_10_3390_biomedicines10081847 crossref_primary_10_1038_s41429_020_0344_z crossref_primary_10_1016_j_drudis_2021_03_031 crossref_primary_10_1111_nyas_14596 crossref_primary_10_1089_jmf_2020_0135 crossref_primary_10_3389_fcimb_2018_00404 crossref_primary_10_3390_molecules27238348 crossref_primary_10_1099_acmi_0_000132 crossref_primary_10_1038_s41427_022_00420_5 crossref_primary_10_1111_mmi_14797 crossref_primary_10_3103_S0891416820010073 crossref_primary_10_1002_anie_201804971 crossref_primary_10_3390_pathogens8040257 crossref_primary_10_12688_f1000research_19509_1 crossref_primary_10_3390_biom11020316 |
| Cites_doi | 10.1016/j.vaccine.2009.11.076 10.1016/j.vaccine.2011.06.119 10.1128/AAC.02643-14 10.1038/nrmicro2199 10.1371/journal.ppat.1003047 10.1086/533452 10.1046/j.1365-2958.1997.5411905.x 10.1016/S0190-9622(83)70017-4 10.1128/AAC.00975-12 10.1093/infdis/jir552 10.1172/JCI89652 10.1128/AAC.02795-13 10.1086/649554 10.1128/IAI.00501-09 10.1111/j.1365-2230.2008.03020.x 10.1093/infdis/139.3.288 10.1016/j.ajpath.2010.12.028 10.1097/MD.0000000000005507 10.1016/j.bmc.2015.01.011 10.1126/scitranslmed.3009655 10.1056/NEJM200108023450504 10.1086/668770 10.1007/s00294-015-0522-x 10.1016/S1534-5807(03)00019-4 10.1046/j.1365-2958.1999.01359.x 10.1159/000360006 10.1111/j.1348-0421.2009.00165.x 10.1007/s10096-014-2277-6 10.1371/journal.ppat.1004945 10.1006/plas.1999.1441 10.1016/j.jcf.2005.06.003 10.1086/377200 10.1097/CCM.0b013e31825334f6 10.1128/IAI.72.12.6969-6977.2004 10.1128/IAI.73.4.2262-2272.2005 10.1128/mBio.00140-17 10.1038/jid.2011.462 10.3390/ijerph13090919 10.1128/AAC.01492-06 10.1002/ppul.22890 10.1186/1476-8518-1-2 10.1128/AAC.01598-09 10.1097/00006454-200212000-00016 10.1128/mBio.01080-14 10.1074/jbc.274.51.36369 10.1016/S0021-9258(18)65874-0 10.1016/S0255-0857(21)02534-2 10.1128/iai.65.2.579-586.1997 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 American Society for Microbiology. Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
| Copyright_xml | – notice: Copyright © 2017 American Society for Microbiology. – notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1128/AAC.01202-17 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Type III Secretion Inhibitors and Abscess Formation, Berube et al Type III Secretion Inhibitors and Abscess Formation |
| EISSN | 1098-6596 |
| ExternalDocumentID | 10_1128_AAC_01202_17 01202-17 28807906 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI099269 – fundername: NIAID NIH HHS grantid: R44 AI068185 – fundername: NIAID NIH HHS grantid: R01 AI053674 – fundername: Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator grantid: CARB-X4500002329 – fundername: HHS | National Institutes of Health (NIH) grantid: K24 AI04831; R01 AI053674 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: R44 AI068185; R01 AI099269 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: K24 AI04831; R01 AI053674 – fundername: HHS | National Institutes of Health (NIH) grantid: R44 AI068185; R01 AI099269 |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AFMIJ AGNAY AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD F5P FRP GX1 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZA5 ZGI ZXP ~A~ - 0R 55 AAPBV ABFLS ADACO BXI H13 HZ AAYXX AGVNZ CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-a418t-9b51939fa4daae05bd3908e45002a6ede44c75043701cfe2bc885b676b0ad5dd3 |
| IEDL.DBID | RPM |
| ISSN | 0066-4804 |
| IngestDate | Tue Sep 17 20:40:14 EDT 2024 Wed Jul 24 16:05:42 EDT 2024 Thu Sep 12 17:21:10 EDT 2024 Tue Dec 28 13:59:07 EST 2021 Fri May 24 00:05:37 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | abscesses Pseudomonas aeruginosa phenoxyacetamide inhibitors neutrophils type III secretion |
| Language | English |
| License | Copyright © 2017 American Society for Microbiology. All Rights Reserved . https://doi.org/10.1128/ASMCopyrightv2 All Rights Reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a418t-9b51939fa4daae05bd3908e45002a6ede44c75043701cfe2bc885b676b0ad5dd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Bryan J. Berube, Infectious Disease Research Institute, Seattle, Washington, USA. Citation Berube BJ, Murphy KR, Torhan MC, Bowlin NO, Williams JD, Bowlin TL, Moir DT, Hauser AR. 2017. Impact of type III secretion effectors and of phenoxyacetamide inhibitors of type III secretion on abscess formation in a mouse model of Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 61:e01202-17. https://doi.org/10.1128/AAC.01202-17. |
| OpenAccessLink | https://aac.asm.org/content/aac/61/11/e01202-17.full.pdf |
| PMID | 28807906 |
| PQID | 1929105606 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5655109 proquest_miscellaneous_1929105606 crossref_primary_10_1128_AAC_01202_17 asm2_journals_10_1128_AAC_01202_17 pubmed_primary_28807906 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-11-01 |
| PublicationDateYYYYMMDD | 2017-11-01 |
| PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2017 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | 17502403 - Antimicrob Agents Chemother. 2007 Jul;51(7):2631-5 21763383 - Vaccine. 2011 Sep 2;29(38):6572-83 19680249 - Nat Rev Microbiol. 2009 Sep;7(9):654-65 19094136 - Clin Exp Dermatol. 2009 Jul;34(5):e180-2 13278318 - J Biol Chem. 1956 Jan;218(1):97-106 11484690 - N Engl J Med. 2001 Aug 2;345(5):335-8 26407972 - Curr Genet. 2016 Feb;62(1):109-13 27649225 - Int J Environ Res Public Health. 2016 Sep 15;13(9):null 19805527 - Infect Immun. 2009 Dec;77(12):5300-10 24820433 - J Innate Immun. 2014;6(5):619-31 19903258 - Microbiol Immunol. 2009 Nov;53(11):587-94 25638499 - Bioorg Med Chem. 2015 Mar 1;23(5):1027-43 24019259 - Pediatr Pulmonol. 2014 Jul;49(7):650-8 24841258 - Antimicrob Agents Chemother. 2014 Aug;58(8):4384-91 12586068 - Dev Cell. 2003 Feb;4(2):253-63 22377761 - J Invest Dermatol. 2012 May;132(5):1513-6 23221186 - Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14 28246361 - MBio. 2017 Feb 28;8(1):null 28079790 - Medicine (Baltimore). 2017 Jan;96(2):e5507 12488670 - Pediatr Infect Dis J. 2002 Dec;21(12):1161-4 22850518 - Antimicrob Agents Chemother. 2012 Nov;56(11):5433-41 109545 - J Infect Dis. 1979 Mar;139(3):288-96 16327125 - Indian J Med Microbiol. 2005 Oct;23(4):262-3 15557619 - Infect Immun. 2004 Dec;72(12):6969-77 12955633 - Clin Infect Dis. 2003 Sep 15;37(6):745-51 20176902 - Antimicrob Agents Chemother. 2010 May;54(5):1988-99 21933873 - J Infect Dis. 2011 Nov;204(9):1313-20 16081326 - J Cyst Fibros. 2005 Dec;4(4):227-31 22622405 - Crit Care Med. 2012 Aug;40(8):2320-6 15784570 - Infect Immun. 2005 Apr;73(4):2262-72 6402527 - J Am Acad Dermatol. 1983 Feb;8(2):153-6 26090668 - PLoS Pathog. 2015 Jun 19;11(6):e1004945 25391481 - Sci Transl Med. 2014 Nov 12;6(262):262ra155 24917597 - MBio. 2014 Jun 10;5(3):e01080-14 24468789 - Antimicrob Agents Chemother. 2014;58(4):2211-20 10231494 - Mol Microbiol. 1999 Apr;32(2):393-401 23209417 - PLoS Pathog. 2012;8(11):e1003047 10610820 - Plasmid. 2000 Jan;43(1):59-72 25407372 - Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):633-9 20005318 - Vaccine. 2010 Feb 17;28(7):1870-6 28463232 - J Clin Invest. 2017 Jun 1;127(6):2249-2261 20034345 - Clin Infect Dis. 2010 Jan 15;50(2):133-64 9009316 - Infect Immun. 1997 Feb;65(2):579-86 21406168 - Am J Pathol. 2011 Apr;178(4):1689-700 12943554 - J Immune Based Ther Vaccines. 2003 Aug 13;1(1):2 18419525 - J Infect Dis. 2008 Apr 15;197(8):1079-81 9350868 - Mol Microbiol. 1997 Sep;25(6):1125-39 10593930 - J Biol Chem. 1999 Dec 17;274(51):36369-72 Moriyama, K, Wiener-Kronish, JP, Sawa, T (B38) 2009; 53 Berube, BJ, Rangel, SM, Hauser, AR (B22) 2016; 62 Rangel, SM, Logan, LK, Hauser, AR (B11) 2014; 5 Aiello, D, Williams, JD, Majgier-Baranowska, H, Patel, I, Peet, NP, Huang, J, Lory, S, Bowlin, TL, Moir, DT (B12) 2010; 54 Vaiman, M, Lazarovitch, T, Heller, L, Lotan, G (B28) 2015; 34 Wolfgang, MC, Lee, VT, Gilmore, ME, Lory, S (B47) 2003; 4 Hudson, DL, Layton, AN, Field, TR, Bowen, AJ, Wolf-Watz, H, Elofsson, M, Stevens, MP, Galyov, EE (B43) 2007; 51 Solomkin, JS, Mazuski, JE, Bradley, JS, Rodvold, KA, Goldstein, EJ, Baron, EJ, O'Neill, PJ, Chow, AW, Dellinger, EP, Eachempati, SR, Gorbach, S, Hilfiker, M, May, AK, Nathens, AB, Sawyer, RG, Bartlett, JG (B4) 2010; 50 Cho, JS, Guo, Y, Ramos, RI, Hebroni, F, Plaisier, SB, Xuan, C, Granick, JL, Matsushima, H, Takashima, A, Iwakura, Y, Cheung, AL, Cheng, G, Lee, DJ, Simon, SI, Miller, LS (B20) 2012; 8 Williams, JD, Torhan, MC, Neelagiri, VR, Brown, C, Bowlin, NO, Di, M, McCarthy, CT, Aiello, D, Peet, NP, Bowlin, TL, Moir, DT (B14) 2015; 23 Milla, CE, Chmiel, JF, Accurso, FJ, VanDevanter, DR, Konstan, MW, Yarranton, G, Geller, DE (B41) 2014; 49 Francois, B, Luyt, CE, Dugard, A, Wolff, M, Diehl, JL, Jaber, S, Forel, JM, Garot, D, Kipnis, E, Mebazaa, A, Misset, B, Andremont, A, Ploy, MC, Jacobs, A, Yarranton, G, Pearce, T, Fagon, JY, Chastre, J (B40) 2012; 40 Bowlin, NO, Williams, JD, Knoten, CA, Torhan, MC, Tashjian, TF, Li, B, Aiello, D, Mecsas, J, Hauser, AR, Peet, NP, Bowlin, TL, Moir, DT (B13) 2014; 58 Ziegler, EJ, Douglas, H (B27) 1979; 139 Guida, M, Di Onofrio, V, Galle, F, Gesuele, R, Valeriani, F, Liguori, R, Romano Spica, V, Liguori, G (B24) 2016; 13 Duncan, MC, Linington, RG, Auerbuch, V (B33) 2012; 56 Singh, TN, Devi, KM, Devi, KS (B31) 2005; 23 Koh, AY, Priebe, GP, Ray, C, Van Rooijen, N, Pier, GB (B19) 2009; 77 Quenee, LE, Ciletti, NA, Elli, D, Hermanas, TM, Schneewind, O (B36) 2011; 29 Inoshima, N, Wang, Y, Wardenburg, JB (B48) 2012; 132 Biscaye, S, Demonchy, D, Afanetti, M, Dupont, A, Haas, H, Tran, A (B29) 2017; 96 Faure, K, Fujimoto, J, Shimabukuro, DW, Ajayi, T, Shime, N, Moriyama, K, Spack, EG, Wiener-Kronish, JP, Sawa, T (B37) 2003; 1 Shaver, CM, Hauser, AR (B45) 2004; 72 Pederson, KJ, Vallis, AJ, Aktories, K, Frank, DW, Barbieri, JT (B9) 1999; 32 Slepenkin, A, Chu, H, Elofsson, M, Keyser, P, Peterson, EM (B44) 2011; 204 Zomorrodi, A, Wald, ER (B32) 2002; 21 Quenee, LE, Berube, BJ, Segal, J, Elli, D, Ciletti, NA, Anderson, D, Schneewind, O (B34) 2010; 28 Thanabalasuriar, A, Surewaard, BGJ, Willson, ME, Neupane, AS, Stover, CK, Warrener, P, Wilson, G, Keller, AE, Sellman, BR, DiGiandomenico, A, Kubes, P (B18) 2017; 127 Pletzer, D, Mansour, SC, Wuerth, K, Rahanjam, N, Hancock, RE (B15) 2017; 8 DiGiandomenico, A, Keller, AE, Gao, C, Rainey, GJ, Warrener, P, Camara, MM, Bonnell, J, Fleming, R, Bezabeh, B, Dimasi, N, Sellman, BR, Hilliard, J, Guenther, CM, Datta, V, Zhao, W, Gao, C, Yu, XQ, Suzich, JA, Stover, CK (B42) 2014; 6 Fleiszig, SM, Wiener-Kronish, JP, Miyazaki, H, Vallas, V, Mostov, KE, Kanada, D, Sawa, T, Yen, TS, Frank, DW (B16) 1997; 65 Quenee, LE, Ciletti, N, Berube, B, Krausz, T, Elli, D, Hermanas, T, Schneewind, O (B35) 2011; 178 Frithz-Lindsten, E, Du, Y, Rosqvist, R, Forsberg, A (B17) 1997; 25 Goolamali, SI, Fogo, A, Killian, L, Shaikh, H, Brathwaite, N, Ford-Adams, M, Macfarlane, S (B30) 2009; 34 Hauser, AR (B7) 2009; 7 Rangel, SM, Diaz, MH, Knoten, CA, Zhang, A, Hauser, AR (B10) 2015; 11 Rice, LB (B6) 2008; 197 Sievert, DM, Ricks, P, Edwards, JR, Schneider, A, Patel, J, Srinivasan, A, Kallen, A, Limbago, B, Fridkin, S (B5) 2013; 34 Hoang, TT, Kutchma, AJ, Becher, A, Schweizer, HP (B46) 2000; 43 Warrener, P, Varkey, R, Bonnell, JC, DiGiandomenico, A, Camara, M, Cook, K, Peng, L, Zha, J, Chowdury, P, Sellman, B, Stover, CK (B39) 2014; 58 Becker, RE, Berube, BJ, Sampedro, GR, Dedent, AC, Bubeck Wardenburg, J (B21) 2014; 6 Barben, J, Hafen, G, Schmid, J (B23) 2005; 4 Fiorillo, L, Zucker, M, Sawyer, D, Lin, AN (B2) 2001; 345 Kang, CI, Kim, SH, Kim, HB, Park, SW, Choe, YJ, Oh, MD, Kim, EC, Choe, KW (B25) 2003; 37 Stryjewski, M, Sexton, DJ, Hauser, A, Rello, J (B1) 2003 Silverman, AR, Nieland, ML (B3) 1983; 8 Goehring, UM, Schmidt, G, Pederson, KJ, Aktories, K, Barbieri, JT (B8) 1999; 274 Koh, AY, Priebe, GP, Pier, GB (B26) 2005; 73 Vogel, HJ, Bonner, DM (B49) 1956; 218 e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 Stryjewski M (e_1_3_2_2_2) 2003 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 |
| References_xml | – volume: 28 start-page: 1870 year: 2010 end-page: 1876 ident: B34 article-title: Amino acid residues 196-225 of LcrV represent a plague protective epitope publication-title: Vaccine doi: 10.1016/j.vaccine.2009.11.076 contributor: fullname: Schneewind, O – volume: 29 start-page: 6572 year: 2011 end-page: 6583 ident: B36 article-title: Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2011.06.119 contributor: fullname: Schneewind, O – volume: 58 start-page: 4384 year: 2014 end-page: 4391 ident: B39 article-title: A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02643-14 contributor: fullname: Stover, CK – volume: 218 start-page: 97 year: 1956 end-page: 106 ident: B49 article-title: Acetylornithinase of Escherichia coli: partial purification and some properties publication-title: J Biol Chem contributor: fullname: Bonner, DM – volume: 7 start-page: 654 year: 2009 end-page: 665 ident: B7 article-title: The type III secretion system of Pseudomonas aeruginosa: infection by injection publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro2199 contributor: fullname: Hauser, AR – volume: 8 year: 2012 ident: B20 article-title: Neutrophil-derived IL-1beta is sufficient for abscess formation in immunity against Staphylococcus aureus in mice publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1003047 contributor: fullname: Miller, LS – volume: 197 start-page: 1079 year: 2008 end-page: 1081 ident: B6 article-title: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE publication-title: J Infect Dis doi: 10.1086/533452 contributor: fullname: Rice, LB – volume: 25 start-page: 1125 year: 1997 end-page: 1139 ident: B17 article-title: Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments publication-title: Mol Microbiol doi: 10.1046/j.1365-2958.1997.5411905.x contributor: fullname: Forsberg, A – volume: 8 start-page: 153 year: 1983 end-page: 156 ident: B3 article-title: Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis publication-title: J Am Acad Dermatol doi: 10.1016/S0190-9622(83)70017-4 contributor: fullname: Nieland, ML – volume: 56 start-page: 5433 year: 2012 end-page: 5441 ident: B33 article-title: Chemical inhibitors of the type three secretion system: disarming bacterial pathogens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00975-12 contributor: fullname: Auerbuch, V – volume: 204 start-page: 1313 year: 2011 end-page: 1320 ident: B44 article-title: Protection of mice from a Chlamydia trachomatis vaginal infection using a salicylidene acylhydrazide, a potential microbicide publication-title: J Infect Dis doi: 10.1093/infdis/jir552 contributor: fullname: Peterson, EM – volume: 127 start-page: 2249 year: 2017 end-page: 2261 ident: B18 article-title: Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature publication-title: J Clin Invest doi: 10.1172/JCI89652 contributor: fullname: Kubes, P – start-page: 1 year: 2003 end-page: 15 ident: B1 article-title: Pseudomonas aeruginosa infections in specific types of patients and clinical settings publication-title: Severe infections caused by Pseudomonas aeruginosa ;Kluwer Academic Publishers ;Boston, MA contributor: fullname: Rello, J – volume: 58 start-page: 2211 year: 2014 end-page: 2220 ident: B13 article-title: Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02795-13 contributor: fullname: Moir, DT – volume: 50 start-page: 133 year: 2010 end-page: 164 ident: B4 article-title: Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America publication-title: Clin Infect Dis doi: 10.1086/649554 contributor: fullname: Bartlett, JG – volume: 77 start-page: 5300 year: 2009 end-page: 5310 ident: B19 article-title: Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia publication-title: Infect Immun doi: 10.1128/IAI.00501-09 contributor: fullname: Pier, GB – volume: 65 start-page: 579 year: 1997 end-page: 586 ident: B16 article-title: Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S publication-title: Infect Immun contributor: fullname: Frank, DW – volume: 34 start-page: e180 year: 2009 end-page: e182 ident: B30 article-title: Ecthyma gangrenosum: an important feature of pseudomonal sepsis in a previously well child publication-title: Clin Exp Dermatol doi: 10.1111/j.1365-2230.2008.03020.x contributor: fullname: Macfarlane, S – volume: 139 start-page: 288 year: 1979 end-page: 296 ident: B27 article-title: Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonas infection in neutropenia publication-title: J Infect Dis doi: 10.1093/infdis/139.3.288 contributor: fullname: Douglas, H – volume: 178 start-page: 1689 year: 2011 end-page: 1700 ident: B35 article-title: Plague in guinea pigs and its prevention by subunit vaccines publication-title: Am J Pathol doi: 10.1016/j.ajpath.2010.12.028 contributor: fullname: Schneewind, O – volume: 96 year: 2017 ident: B29 article-title: Ecthyma gangrenosum, a skin manifestation of Pseudomonas aeruginosa sepsis in a previously healthy child: a case report publication-title: Medicine doi: 10.1097/MD.0000000000005507 contributor: fullname: Tran, A – volume: 23 start-page: 1027 year: 2015 end-page: 1043 ident: B14 article-title: Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS) publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2015.01.011 contributor: fullname: Moir, DT – volume: 6 start-page: 262ra155 year: 2014 ident: B42 article-title: A multifunctional bispecific antibody protects against Pseudomonas aeruginosa publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3009655 contributor: fullname: Stover, CK – volume: 345 start-page: 335 year: 2001 end-page: 338 ident: B2 article-title: The Pseudomonas hot-foot syndrome publication-title: N Engl J Med doi: 10.1056/NEJM200108023450504 contributor: fullname: Lin, AN – volume: 34 start-page: 1 year: 2013 end-page: 14 ident: B5 article-title: Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/668770 contributor: fullname: Fridkin, S – volume: 62 start-page: 109 year: 2016 end-page: 113 ident: B22 article-title: Pseudomonas aeruginosa: breaking down barriers publication-title: Curr Genet doi: 10.1007/s00294-015-0522-x contributor: fullname: Hauser, AR – volume: 4 start-page: 253 year: 2003 end-page: 263 ident: B47 article-title: Coordinate regulation of bacterial virulence genes by a novel adenylate cyclase-dependent signaling pathway publication-title: Dev Cell doi: 10.1016/S1534-5807(03)00019-4 contributor: fullname: Lory, S – volume: 32 start-page: 393 year: 1999 end-page: 401 ident: B9 article-title: The amino-terminal domain of Pseudomonas aeruginosa ExoS disrupts actin filaments via small-molecular-weight GTP-binding proteins publication-title: Mol Microbiol doi: 10.1046/j.1365-2958.1999.01359.x contributor: fullname: Barbieri, JT – volume: 6 start-page: 619 year: 2014 end-page: 631 ident: B21 article-title: Tissue-specific patterning of host innate immune responses by Staphylococcus aureus alpha-toxin publication-title: J Innate Immun doi: 10.1159/000360006 contributor: fullname: Bubeck Wardenburg, J – volume: 23 start-page: 262 year: 2005 end-page: 263 ident: B31 article-title: Ecthyma gangrenosum: a rare cutaneous manifestation caused by Pseudomonas aeruginosa without bacteraemia in a leukaemic patient—a case report publication-title: Indian J Med Microbiol contributor: fullname: Devi, KS – volume: 53 start-page: 587 year: 2009 end-page: 594 ident: B38 article-title: Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice publication-title: Microbiol Immunol doi: 10.1111/j.1348-0421.2009.00165.x contributor: fullname: Sawa, T – volume: 34 start-page: 633 year: 2015 end-page: 639 ident: B28 article-title: Ecthyma gangrenosum and ecthyma-like lesions: review article publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-014-2277-6 contributor: fullname: Lotan, G – volume: 11 year: 2015 ident: B10 article-title: The role of ExoS in dissemination of Pseudomonas aeruginosa during pneumonia publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1004945 contributor: fullname: Hauser, AR – volume: 43 start-page: 59 year: 2000 end-page: 72 ident: B46 article-title: Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains publication-title: Plasmid doi: 10.1006/plas.1999.1441 contributor: fullname: Schweizer, HP – volume: 4 start-page: 227 year: 2005 end-page: 231 ident: B23 article-title: Pseudomonas aeruginosa in public swimming pools and bathroom water of patients with cystic fibrosis publication-title: J Cyst Fibros doi: 10.1016/j.jcf.2005.06.003 contributor: fullname: Schmid, J – volume: 37 start-page: 745 year: 2003 end-page: 751 ident: B25 article-title: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome publication-title: Clin Infect Dis doi: 10.1086/377200 contributor: fullname: Choe, KW – volume: 40 start-page: 2320 year: 2012 end-page: 2326 ident: B40 article-title: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial publication-title: Crit Care Med doi: 10.1097/CCM.0b013e31825334f6 contributor: fullname: Chastre, J – volume: 72 start-page: 6969 year: 2004 end-page: 6977 ident: B45 article-title: Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung publication-title: Infect Immun doi: 10.1128/IAI.72.12.6969-6977.2004 contributor: fullname: Hauser, AR – volume: 73 start-page: 2262 year: 2005 end-page: 2272 ident: B26 article-title: Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia publication-title: Infect Immun doi: 10.1128/IAI.73.4.2262-2272.2005 contributor: fullname: Pier, GB – volume: 8 year: 2017 ident: B15 article-title: New mouse model for chronic infections by Gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions publication-title: mBio doi: 10.1128/mBio.00140-17 contributor: fullname: Hancock, RE – volume: 132 start-page: 1513 year: 2012 end-page: 1516 ident: B48 article-title: Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection publication-title: J Investig Dermatol doi: 10.1038/jid.2011.462 contributor: fullname: Wardenburg, JB – volume: 13 start-page: E919 year: 2016 ident: B24 article-title: Pseudomonas aeruginosa in swimming pool water: evidences and perspectives for a new control strategy publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph13090919 contributor: fullname: Liguori, G – volume: 51 start-page: 2631 year: 2007 end-page: 2635 ident: B43 article-title: Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01492-06 contributor: fullname: Galyov, EE – volume: 49 start-page: 650 year: 2014 end-page: 658 ident: B41 article-title: Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection publication-title: Pediatr Pulmonol doi: 10.1002/ppul.22890 contributor: fullname: Geller, DE – volume: 1 start-page: 2 year: 2003 ident: B37 article-title: Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model publication-title: J Immune Based Ther Vaccines doi: 10.1186/1476-8518-1-2 contributor: fullname: Sawa, T – volume: 54 start-page: 1988 year: 2010 end-page: 1999 ident: B12 article-title: Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01598-09 contributor: fullname: Moir, DT – volume: 21 start-page: 1161 year: 2002 end-page: 1164 ident: B32 article-title: Ecthyma gangrenosum: considerations in a previously healthy child publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-200212000-00016 contributor: fullname: Wald, ER – volume: 5 year: 2014 ident: B11 article-title: The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia publication-title: mBio doi: 10.1128/mBio.01080-14 contributor: fullname: Hauser, AR – volume: 274 start-page: 36369 year: 1999 end-page: 36372 ident: B8 article-title: The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases publication-title: J Biol Chem doi: 10.1074/jbc.274.51.36369 contributor: fullname: Barbieri, JT – ident: e_1_3_2_45_2 doi: 10.1093/infdis/jir552 – ident: e_1_3_2_27_2 doi: 10.1128/IAI.73.4.2262-2272.2005 – ident: e_1_3_2_50_2 doi: 10.1016/S0021-9258(18)65874-0 – ident: e_1_3_2_13_2 doi: 10.1128/AAC.01598-09 – ident: e_1_3_2_15_2 doi: 10.1016/j.bmc.2015.01.011 – ident: e_1_3_2_22_2 doi: 10.1159/000360006 – ident: e_1_3_2_41_2 doi: 10.1097/CCM.0b013e31825334f6 – ident: e_1_3_2_26_2 doi: 10.1086/377200 – ident: e_1_3_2_5_2 doi: 10.1086/649554 – ident: e_1_3_2_36_2 doi: 10.1016/j.ajpath.2010.12.028 – ident: e_1_3_2_12_2 doi: 10.1128/mBio.01080-14 – ident: e_1_3_2_47_2 doi: 10.1006/plas.1999.1441 – ident: e_1_3_2_8_2 doi: 10.1038/nrmicro2199 – ident: e_1_3_2_23_2 doi: 10.1007/s00294-015-0522-x – ident: e_1_3_2_32_2 doi: 10.1016/S0255-0857(21)02534-2 – ident: e_1_3_2_16_2 doi: 10.1128/mBio.00140-17 – ident: e_1_3_2_37_2 doi: 10.1016/j.vaccine.2011.06.119 – ident: e_1_3_2_39_2 doi: 10.1111/j.1348-0421.2009.00165.x – ident: e_1_3_2_7_2 doi: 10.1086/533452 – ident: e_1_3_2_42_2 doi: 10.1002/ppul.22890 – ident: e_1_3_2_19_2 doi: 10.1172/JCI89652 – ident: e_1_3_2_29_2 doi: 10.1007/s10096-014-2277-6 – ident: e_1_3_2_3_2 doi: 10.1056/NEJM200108023450504 – ident: e_1_3_2_44_2 doi: 10.1128/AAC.01492-06 – ident: e_1_3_2_18_2 doi: 10.1046/j.1365-2958.1997.5411905.x – ident: e_1_3_2_21_2 doi: 10.1371/journal.ppat.1003047 – ident: e_1_3_2_31_2 doi: 10.1111/j.1365-2230.2008.03020.x – ident: e_1_3_2_10_2 doi: 10.1046/j.1365-2958.1999.01359.x – ident: e_1_3_2_38_2 doi: 10.1186/1476-8518-1-2 – ident: e_1_3_2_43_2 doi: 10.1126/scitranslmed.3009655 – ident: e_1_3_2_17_2 doi: 10.1128/iai.65.2.579-586.1997 – ident: e_1_3_2_9_2 doi: 10.1074/jbc.274.51.36369 – ident: e_1_3_2_35_2 doi: 10.1016/j.vaccine.2009.11.076 – ident: e_1_3_2_14_2 doi: 10.1128/AAC.02795-13 – ident: e_1_3_2_6_2 doi: 10.1086/668770 – ident: e_1_3_2_46_2 doi: 10.1128/IAI.72.12.6969-6977.2004 – ident: e_1_3_2_33_2 doi: 10.1097/00006454-200212000-00016 – ident: e_1_3_2_30_2 doi: 10.1097/MD.0000000000005507 – ident: e_1_3_2_24_2 doi: 10.1016/j.jcf.2005.06.003 – ident: e_1_3_2_34_2 doi: 10.1128/AAC.00975-12 – ident: e_1_3_2_20_2 doi: 10.1128/IAI.00501-09 – ident: e_1_3_2_49_2 doi: 10.1038/jid.2011.462 – ident: e_1_3_2_48_2 doi: 10.1016/S1534-5807(03)00019-4 – ident: e_1_3_2_4_2 doi: 10.1016/S0190-9622(83)70017-4 – ident: e_1_3_2_28_2 doi: 10.1093/infdis/139.3.288 – start-page: 1 volume-title: Severe infections caused by Pseudomonas aeruginosa year: 2003 ident: e_1_3_2_2_2 contributor: fullname: Stryjewski M – ident: e_1_3_2_11_2 doi: 10.1371/journal.ppat.1004945 – ident: e_1_3_2_40_2 doi: 10.1128/AAC.02643-14 – ident: e_1_3_2_25_2 doi: 10.3390/ijerph13090919 |
| SSID | ssj0006590 |
| Score | 2.4702082 |
| Snippet | is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve macro- or microabscess... Pseudomonas aeruginosa is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve... ABSTRACT Pseudomonas aeruginosa is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may... Pseudomonas aeruginosa is a leading cause of intra-abdominal infections, wound infections, and community-acquired folliculitis, each of which may involve... |
| SourceID | pubmedcentral proquest crossref asm2 pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| SubjectTerms | Abscess Anti-Bacterial Agents Experimental Therapeutics Pseudomonas aeruginosa Pseudomonas Infections |
| Title | Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28807906 https://journals.asm.org/doi/10.1128/AAC.01202-17 https://search.proquest.com/docview/1929105606 https://pubmed.ncbi.nlm.nih.gov/PMC5655109 |
| Volume | 61 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbWSiBeEJRbuUwGwZ6WNhfbcR6rimoFFRWxSXuLfMsaaXWmppXoT-JfcuwkG-XygpS3nNhRzsWf43O-g9D7lHCjKFNBzBQNiBAFuJRSQSpYQgpYoTLps3y_sLML8umSXh4h2tXC-KR9JcuRvV6PbLnyuZU3azXu8sTGy8UUQAiYUjbuoV6aJN0WvQ2_jDY_VmAtDQgPSZftHvPxZDIduWLROIhc870YbDfNXK-jvqjX8eHK9Afc_D1r8pdlaPYIPWzxI5407_kYHRk7QPeajpL7Abq_aM_KB-hk2bBS70_x-V2RVX2KT_Dyjq96_wT9mPtKSVwV2O1K8Xw-x98cmnQ6ww29cbWpsbDaySxXxlbf90KZrViXGuTtqpSlF_n7EHBNIDxBTMWzrlYSlxYLvKh2tcGuH9u1H7o2O12BYwiYzWx2V6WtagETNAlj9im6mH08n54FbQeHQJCIbwNQNADErBBEC2FCKnWShdwQCnFYMKMNIcrxyydpGKnCxFJxTiVLmQyFplonz1DfVta8QDgqMhkTJhx_PpFa8DSRiVHE0JhLTsMheueUmLcuWOd-dxPzHJSee6XnUTpEHzoV5zcNm8c_5N52-s_B3dwZirAGPkkOgBgAFsBENkTPG3u4HamzpyFKDyzlVsBReR_eAQv3lN6tRb_87ydfoQexAxy-SvI16m83O_MG4NJWHqPe56_82DvJT3hfFSY |
| link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWIh4XHuVVngbBnjZp6tiJc6wqqha2q0p00d4i23HUiK2zatpD-Uf8S8ZOsksXOICUmyeObH1jf45nvkHofUy5VixSHokU86gQObiUUl4sopDmsEMl0kX5nkSTU_rpjJ0dINbmwrigfSUL35yvfFMsXWzlxUr12zix_nw2AhICUEr6N9BN8FcSt4f0ZgGOWP1rBXZTj_KAtvHuhPeHw5Fv00WJN7Dl9wigN05staOOqFZkf2_6jXBej5v8ZSMa30df2yHU8Sff_O1G-ur7NXXHfx7jA3SvoaZ4WDc_RAfadNGtuljlrotuz5pr-C46nNeC17sjvLjK36qO8CGeX0lh7x6hH1OXhInLHNsDL55Op_iLJaoWDrhWTi7XFRYmszbzpTYwKqH0RqyKDOzNspCFM_lzF_AMYeWD5RqP2zRMXBgs8KzcVhrbUm_nrutKb7MSfE7A1_R6C7NVVgI-UMeimcfodPxxMZp4TXEIT9AB33iAIeCeSS5oJoQOmMzCJOCaMljiRaQzTamy0vVhHAxUrolUnDMZxZEMRMayLHyCOqY0-hnCgzyRhEbCSvNTmQkehzLUimpGuOQs6KF3Fh1p491V6g5OhKeAptShKR3EPfShxU56UQuF_MXubQusFDzZXs8Io2FKUuDawN2AgUY99LQG2mVPLVB7KN6D4KWBVQnfbwFgObXwBkjP__vNN-jOZDE7To-nJ59foLvE8hqXjPkSdTbrrX4FrGwjXzsf_AlbsDYo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLagiImXAeWycjUI9rSkqeMkzmNVqFagUyU2aeIl8i1qxOpUTftQ_hH_kmMn2dYBL5PylhNbtr5jf47P-Q5CHxLKtIxi6ZFYRh7lPAeXktJLeBzSHHaoVLgo35P4-Ix-OY_Or5X6ckH7UhS-uVj4ppi72MrlQvbbOLH-bDoCEgJQSvtLlffvonvgsyRtD-rNIhxH9e8V2FE9ygLaxrwT1h8OR75NGSXewJbgI4DgJLUVjzq8WpDd_ekv0nkzdvLaZjR-iH60w6hjUH76m7Xw5a8bCo-3GucjtN9QVDysTR6jO9p00f26aOW2i_amzXV8Fx3OauHr7RE-vcrjqo7wIZ5dSWJvn6DfE5eMicsc24Mvnkwm-LslrBYWuFZQLlcV5kZZm9lcGxgZl3rNF4UCezMvROFM_t0EPENYAWHZxuM2HRMXBnM8LTeVxrbk24VrutIbVYLvcehNrzYwY2XFoYM6Js08RWfjz6ejY68pEuFxOmBrD7AEHDTNOVWc6yASKkwDpmkESz2PtdKUSithHybBQOaaCMlYJOIkFgFXkVLhM9QxpdEHCA_yVBAacyvRT4XiLAlFqCXVEWGCRUEPvbcIyRovrzJ3gCIsA0RlDlHZIOmhjy1-smUtGPIfu3ctuDLwaHtNw42GKcmAcwOHAyYa99DzGmyXLbVg7aFkB4aXBlYtfPcNgMuphjdgenHrL9-ivdmncfZtcvL1JXpALL1xOZmvUGe92ujXQM7W4o1zwz8F5jio |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+Type+III+Secretion+Effectors+and+of+Phenoxyacetamide+Inhibitors+of+Type+III+Secretion+on+Abscess+Formation+in+a+Mouse+Model+of+Pseudomonas+aeruginosa+Infection&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Berube%2C+Bryan+J&rft.au=Murphy%2C+Katherine+R&rft.au=Torhan%2C+Matthew+C&rft.au=Bowlin%2C+Nicholas+O&rft.date=2017-11-01&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=61&rft.issue=11&rft_id=info:doi/10.1128%2FAAC.01202-17&rft.externalDocID=01202-17 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |